Related Experiment Video
Updated: Oct 7, 2026
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
One-year inhibition of tumor necrosis factor-alpha: a major success or a larger puzzle?
1Department of Medicine, Division of Rheumatology, Department of Internal Medicine III, Vienna General Hospital, University of Vienna, Vienna, Austria.
Abstract:
The concept suggesting the involvement of the proinflammatory cytokine tumor necrosis factor (TNF)-alpha in the pathogenesis of rheumatoid arthritis (RA) has been demonstrated by several clinical trials targeting TNF-alpha. In addition to reduction of pain and swelling, a dramatic effect of TNF blocking therapies on the progression of joint destruction was shown. Nevertheless, complete remissions of the disease are rare even with these powerful therapeutic agents, and the optimal doses and dosage intervals of TNF blockers remain to be determined. Some insights into the pathogenesis of RA are provided by studying the effects of therapeutic TNF blockade on the biology of the disease. The fact that inflammation is not completely halted and destruction is ongoing in some patients suggests that other mechanisms may also be involved, including other cytokines such as interleukin-1 and interleukin-6. In addition to the necessity of understanding the pathogenic events proximal to TNF-alpha induction, pharmacologic intervention with small molecules in the TNF signaling pathways may constitute a promising strategy.
Insights
Tumor necrosis factor (TNF)-alpha blockers help rheumatoid arthritis (RA) by reducing pain and joint destruction. However, complete remission is rare, indicating other factors like interleukin-1 and -6 may be involved.
Area of Science:
- Immunology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) pathogenesis involves the proinflammatory cytokine tumor necrosis factor (TNF)-alpha.
- Clinical trials targeting TNF-alpha have shown significant benefits in reducing RA symptoms and joint destruction.
Purpose of the Study:
- To investigate the role of TNF-alpha in RA pathogenesis.
- To explore the limitations of current TNF-alpha blocking therapies and identify potential alternative mechanisms.
- To evaluate the impact of TNF blockade on RA disease biology.
Main Methods:
- Review of clinical trial data on TNF-alpha blocking therapies for RA.
- Analysis of RA disease progression and remission rates.
- Examination of cytokine involvement beyond TNF-alpha in RA.
Main Results:
- TNF-alpha blockers effectively reduce pain, swelling, and joint destruction in RA patients.
- Complete disease remission is infrequent despite potent TNF-alpha blockade.
- Ongoing inflammation and destruction in some patients suggest involvement of other cytokines like interleukin-1 and -6.
Conclusions:
- While TNF-alpha is crucial in RA, other inflammatory pathways contribute to disease progression.
- Further research into alternative cytokines and TNF signaling pathways is warranted.
- Optimizing TNF blocker dosage and exploring small molecule inhibitors for TNF signaling pathways may improve RA treatment outcomes.
